Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative

José Teixeira, Ricardo Amorim, Katia Santos, Pedro Soares, Sandipan Datta, Gino A Cortopassi, Teresa L. Serafim, Vilma A. Sardão, Jorge Garrido, Fernanda Borges, Paulo J. Oliveira

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Menadione, also known as vitamin K3, is a 2-methyl-1,4 naphthoquinone with a potent cytotoxic activity mainly resulting from its quinone redox-cycling with production of reactive oxygen species (ROS). Although increased ROS generation is considered a relevant mechanism in cancer cell death, it may not be sufficiently effective to kill cancer cells due to phenotypic adaptations. Therefore, combining ROS-generating agents with other molecules targeting important cancer cell phenotypes can be an effective therapeutic strategy. As mitochondrial dysfunction has been implicated in many human diseases, including cancer, we describe here the discovery of a mitochondrial-directed agent (MitoK3), which was developed by conjugating a TPP cation to the C3 position of the menadione's naphthoquinone ring, increasing its selective accumulation in mitochondria, as well as led to alterations of its redox properties and consequent biological outcome. MitoK3 disturbed the mitochondrial bioenergetic apparatus, with subsequent loss of mitochondrial ATP production. The combinatory strategy of MitoK3 with anticancer agent doxorubicin (DOX) resulted in a degree of cytotoxicity higher than those of the individual molecules, as the combination triggered tumour apoptotic cell death evident by caspase 3/9 activities, probably through mitochondrial destabilization or by interference with mitochondrial redox processes. The results of this investigation support the importance of drug discovery process in developing molecules that can be use as adjuvant therapy in patients with specific cancer subtypes.

Original languageEnglish (US)
Pages (from-to)123-139
Number of pages17
JournalToxicology
Volume393
DOIs
StatePublished - Jan 15 2018

Fingerprint

Vitamin K 3
Derivatives
Reactive Oxygen Species
Cell death
Molecules
Oxidation-Reduction
Neoplasms
Cells
Naphthoquinones
Mitochondria
Cell Death
Cytotoxicity
Caspase 3
Antineoplastic Agents
Doxorubicin
Cations
Tumors
Caspase 9
Adenosine Triphosphate
Drug Discovery

Keywords

  • Doxorubicin
  • Drug discovery
  • Menadione
  • Mitochondria
  • Mitochondriotropic menadione derivative

ASJC Scopus subject areas

  • Toxicology

Cite this

Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative. / Teixeira, José; Amorim, Ricardo; Santos, Katia; Soares, Pedro; Datta, Sandipan; Cortopassi, Gino A; Serafim, Teresa L.; Sardão, Vilma A.; Garrido, Jorge; Borges, Fernanda; Oliveira, Paulo J.

In: Toxicology, Vol. 393, 15.01.2018, p. 123-139.

Research output: Contribution to journalArticle

Teixeira, J, Amorim, R, Santos, K, Soares, P, Datta, S, Cortopassi, GA, Serafim, TL, Sardão, VA, Garrido, J, Borges, F & Oliveira, PJ 2018, 'Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative', Toxicology, vol. 393, pp. 123-139. https://doi.org/10.1016/j.tox.2017.11.014
Teixeira, José ; Amorim, Ricardo ; Santos, Katia ; Soares, Pedro ; Datta, Sandipan ; Cortopassi, Gino A ; Serafim, Teresa L. ; Sardão, Vilma A. ; Garrido, Jorge ; Borges, Fernanda ; Oliveira, Paulo J. / Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative. In: Toxicology. 2018 ; Vol. 393. pp. 123-139.
@article{b007f5e2d6264b10a89930eba1530c5e,
title = "Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative",
abstract = "Menadione, also known as vitamin K3, is a 2-methyl-1,4 naphthoquinone with a potent cytotoxic activity mainly resulting from its quinone redox-cycling with production of reactive oxygen species (ROS). Although increased ROS generation is considered a relevant mechanism in cancer cell death, it may not be sufficiently effective to kill cancer cells due to phenotypic adaptations. Therefore, combining ROS-generating agents with other molecules targeting important cancer cell phenotypes can be an effective therapeutic strategy. As mitochondrial dysfunction has been implicated in many human diseases, including cancer, we describe here the discovery of a mitochondrial-directed agent (MitoK3), which was developed by conjugating a TPP cation to the C3 position of the menadione's naphthoquinone ring, increasing its selective accumulation in mitochondria, as well as led to alterations of its redox properties and consequent biological outcome. MitoK3 disturbed the mitochondrial bioenergetic apparatus, with subsequent loss of mitochondrial ATP production. The combinatory strategy of MitoK3 with anticancer agent doxorubicin (DOX) resulted in a degree of cytotoxicity higher than those of the individual molecules, as the combination triggered tumour apoptotic cell death evident by caspase 3/9 activities, probably through mitochondrial destabilization or by interference with mitochondrial redox processes. The results of this investigation support the importance of drug discovery process in developing molecules that can be use as adjuvant therapy in patients with specific cancer subtypes.",
keywords = "Doxorubicin, Drug discovery, Menadione, Mitochondria, Mitochondriotropic menadione derivative",
author = "Jos{\'e} Teixeira and Ricardo Amorim and Katia Santos and Pedro Soares and Sandipan Datta and Cortopassi, {Gino A} and Serafim, {Teresa L.} and Sard{\~a}o, {Vilma A.} and Jorge Garrido and Fernanda Borges and Oliveira, {Paulo J.}",
year = "2018",
month = "1",
day = "15",
doi = "10.1016/j.tox.2017.11.014",
language = "English (US)",
volume = "393",
pages = "123--139",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative

AU - Teixeira, José

AU - Amorim, Ricardo

AU - Santos, Katia

AU - Soares, Pedro

AU - Datta, Sandipan

AU - Cortopassi, Gino A

AU - Serafim, Teresa L.

AU - Sardão, Vilma A.

AU - Garrido, Jorge

AU - Borges, Fernanda

AU - Oliveira, Paulo J.

PY - 2018/1/15

Y1 - 2018/1/15

N2 - Menadione, also known as vitamin K3, is a 2-methyl-1,4 naphthoquinone with a potent cytotoxic activity mainly resulting from its quinone redox-cycling with production of reactive oxygen species (ROS). Although increased ROS generation is considered a relevant mechanism in cancer cell death, it may not be sufficiently effective to kill cancer cells due to phenotypic adaptations. Therefore, combining ROS-generating agents with other molecules targeting important cancer cell phenotypes can be an effective therapeutic strategy. As mitochondrial dysfunction has been implicated in many human diseases, including cancer, we describe here the discovery of a mitochondrial-directed agent (MitoK3), which was developed by conjugating a TPP cation to the C3 position of the menadione's naphthoquinone ring, increasing its selective accumulation in mitochondria, as well as led to alterations of its redox properties and consequent biological outcome. MitoK3 disturbed the mitochondrial bioenergetic apparatus, with subsequent loss of mitochondrial ATP production. The combinatory strategy of MitoK3 with anticancer agent doxorubicin (DOX) resulted in a degree of cytotoxicity higher than those of the individual molecules, as the combination triggered tumour apoptotic cell death evident by caspase 3/9 activities, probably through mitochondrial destabilization or by interference with mitochondrial redox processes. The results of this investigation support the importance of drug discovery process in developing molecules that can be use as adjuvant therapy in patients with specific cancer subtypes.

AB - Menadione, also known as vitamin K3, is a 2-methyl-1,4 naphthoquinone with a potent cytotoxic activity mainly resulting from its quinone redox-cycling with production of reactive oxygen species (ROS). Although increased ROS generation is considered a relevant mechanism in cancer cell death, it may not be sufficiently effective to kill cancer cells due to phenotypic adaptations. Therefore, combining ROS-generating agents with other molecules targeting important cancer cell phenotypes can be an effective therapeutic strategy. As mitochondrial dysfunction has been implicated in many human diseases, including cancer, we describe here the discovery of a mitochondrial-directed agent (MitoK3), which was developed by conjugating a TPP cation to the C3 position of the menadione's naphthoquinone ring, increasing its selective accumulation in mitochondria, as well as led to alterations of its redox properties and consequent biological outcome. MitoK3 disturbed the mitochondrial bioenergetic apparatus, with subsequent loss of mitochondrial ATP production. The combinatory strategy of MitoK3 with anticancer agent doxorubicin (DOX) resulted in a degree of cytotoxicity higher than those of the individual molecules, as the combination triggered tumour apoptotic cell death evident by caspase 3/9 activities, probably through mitochondrial destabilization or by interference with mitochondrial redox processes. The results of this investigation support the importance of drug discovery process in developing molecules that can be use as adjuvant therapy in patients with specific cancer subtypes.

KW - Doxorubicin

KW - Drug discovery

KW - Menadione

KW - Mitochondria

KW - Mitochondriotropic menadione derivative

UR - http://www.scopus.com/inward/record.url?scp=85034013034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034013034&partnerID=8YFLogxK

U2 - 10.1016/j.tox.2017.11.014

DO - 10.1016/j.tox.2017.11.014

M3 - Article

VL - 393

SP - 123

EP - 139

JO - Toxicology

JF - Toxicology

SN - 0300-483X

ER -